114 results
Page 4 of 6
6-K
EX-99.1
v5cc01
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.1
ecpr78dv
11 Jan 21
ObsEva Provides Update on Yselty® (Linzagolix) Clinical Development Program
7:05am
6-K
EX-99.1
hbs10fe0ols0av43 yzz
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
kov3n9s
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
zat4 0xnb9
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.2
ktyndbm
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-1.1
qwgbxop9pjyma40vq8s
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
j8i8p1h7
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.2
txbz9a wc
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
nd4pu99e
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.3
gu0re g2n535c6
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
l7ce1675dg2fo5
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
chxgnuj9rc87wsbv8jh
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.3
kry nxwka06q9
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
5g3wn zil8
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.2
2is8ep9cej7
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
x0kyxb5pznwxrb2w
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm